AB
VYNE icon

Amalgamated Bank’s VYNE Therapeutics VYNE Stock Holding History

Amalgamated Bank’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-143
Closed -$16K – 1626
2020
Q4 		$16K Hold
143
– – ﹤0.01% 1582
2020
Q3 		$17K Buy
143
+3
+2% +$350 ﹤0.01% 1488
2020
Q2 		$17K Buy
+140
New +$19K ﹤0.01% 1473

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Amalgamated Bank's VYNE Position: Q1 2021 in Review

Amalgamated Bank sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 143 shares — an estimated $16K sold.

Amalgamated Bank first reported a position in VYNE in Q2 2020 and held it in 3 quarters. The position peaked at $17K in Q3 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

  • Amalgamated Bank reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Amalgamated Bank sold 143 VYNE Therapeutics shares in Q1 2021, an estimated $16K.
  • Amalgamated Bank first reported a position in VYNE Therapeutics in Q2 2020 and held it in 3 quarters.
  • Amalgamated Bank's VYNE Therapeutics position peaked at $17K in Q3 2020.
  • 89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on Amalgamated Bank's 13F filing for Q1 2021, filed 13 May 2021.